BSE Live
Mar 30, 16:01Prev. Close
5996.00
Open Price
5995.85
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 30, 15:58Prev. Close
5997.50
Open Price
5960.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
5947.00 (41)
| Key Financial Ratios of Divis Laboratories (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 26.05 | 65.54 | 54.77 | 148.51 | 54.98 | |
| Diluted EPS (Rs.) | 26.05 | 65.54 | 54.77 | 148.51 | 54.98 | |
| Cash EPS (Rs.) | 29.94 | 72.92 | 60.29 | 165.80 | 66.53 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 116.70 | 194.85 | 135.38 | 419.82 | 265.87 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 116.70 | 194.85 | 135.38 | 419.82 | 265.87 | |
| Dividend / Share(Rs.) | 6.00 | 6.00 | 4.00 | 10.00 | 10.00 | |
| Revenue from Operations/Share (Rs.) | 70.50 | 184.28 | 160.38 | 567.62 | 300.79 | |
| PBDIT/Share (Rs.) | 33.38 | 78.78 | 66.38 | 199.75 | 98.35 | |
| PBIT/Share (Rs.) | 29.49 | 71.40 | 60.86 | 182.46 | 86.79 | |
| PBT/Share (Rs.) | 29.40 | 70.78 | 59.59 | 175.58 | 83.40 | |
| Net Profit/Share (Rs.) | 26.05 | 65.54 | 54.77 | 148.51 | 54.98 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 47.34 | 42.75 | 41.38 | 35.19 | 32.69 | |
| PBIT Margin (%) | 41.82 | 38.74 | 37.94 | 32.14 | 28.85 | |
| PBT Margin (%) | 41.69 | 38.40 | 37.15 | 30.93 | 27.72 | |
| Net Profit Margin (%) | 36.94 | 35.56 | 34.14 | 26.16 | 18.27 | |
| Return on Networth / Equity (%) | 22.32 | 33.63 | 40.45 | 35.37 | 20.67 | |
| Return on Capital Employed (%) | 21.20 | 31.16 | 35.93 | 28.87 | 16.40 | |
| Return on Assets (%) | 18.22 | 26.95 | 29.54 | 22.50 | 10.84 | |
| Total Debt/Equity (X) | 0.02 | 0.04 | 0.10 | 0.28 | 0.44 | |
| Asset Turnover Ratio (%) | 49.33 | 75.78 | 86.51 | 86.00 | 59.31 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 3.13 | 3.72 | 2.72 | 2.29 | 1.61 | |
| Quick Ratio (X) | 1.33 | 1.86 | 1.43 | 1.18 | 0.77 | |
| Inventory Turnover Ratio (X) | 1.94 | 3.01 | 3.76 | 3.49 | 2.10 | |
| Dividend Payout Ratio (NP) (%) | 23.03 | 9.16 | 7.30 | 6.73 | 18.18 | |
| Dividend Payout Ratio (CP) (%) | 20.03 | 8.23 | 6.63 | 6.03 | 15.03 | |
| Earnings Retention Ratio (%) | 76.97 | 90.84 | 92.70 | 93.27 | 81.82 | |
| Cash Earnings Retention Ratio (%) | 79.97 | 91.77 | 93.37 | 93.97 | 84.97 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 8,993.22 | 6,215.09 | 8,265.75 | 4,111.57 | 2,539.31 | |
| EV/Net Operating Revenue (X) | 9.65 | 5.21 | 7.98 | 5.61 | 6.59 | |
| EV/EBITDA (X) | 20.39 | 12.18 | 19.29 | 15.94 | 20.14 | |
| MarketCap/Net Operating Revenue (X) | 9.63 | 5.17 | 7.91 | 5.42 | 6.22 | |
| Retention Ratios (%) | 76.96 | 90.83 | 92.69 | 93.26 | 81.81 | |
| Price/BV (X) | 5.82 | 4.89 | 9.37 | 7.33 | 7.04 | |
| Price/Net Operating Revenue | 9.63 | 5.17 | 7.91 | 5.42 | 6.22 | |
| Earnings Yield | 0.04 | 0.07 | 0.04 | 0.05 | 0.03 |
25.02.2026
Divis Labs Consolidated December 2025 Net Sales at Rs 2,604.00 crore, up 12.29% Y-o-Y
25.02.2026
Divis Labs Standalone December 2025 Net Sales at Rs 2,578.00 crore, up 12.23% Y-o-Y
12.02.2026
Accumulate Divis Laboratories; target of Rs 6850: Prabhudas Lilladher
20.11.2025
Accumulate Divis Laboratories; target of Rs 6795: Deven Choksey
25.02.2026
Divis Labs Consolidated December 2025 Net Sales at Rs 2,604.00 crore, up 12.29% Y-o-Y
25.02.2026
Divis Labs Standalone December 2025 Net Sales at Rs 2,578.00 crore, up 12.23% Y-o-Y
14.11.2025
Divis Labs Consolidated September 2025 Net Sales at Rs 2,715.00 crore, up 16.12% Y-o-Y
12.11.2025
Divis Labs Standalone September 2025 Net Sales at Rs 2,660.00 crore, up 15.55% Y-o-Y
24.05.2024
Divi's Labs Q4 preview: Revenue, net profit to grow on normalised base, better product mix
04.11.2023
Divi's Labs Q2 Preview: Earnings likely to improve sequentially on better margins, product mix
14.08.2023
Divi's Labs Q1 Preview: Base effect to pressure earnings, brokerages predict sequential recovery
19.05.2023
Divi's Labs Preview: Unfavourable base, elevated input costs to turn Q4 a sour pill
30.03.2026
Wockhardt novel antibiotic Zaynich gets thumbs-up from CDSCO expert panel
30.03.2026
29.03.2026
27.03.2026
After Biologics merger, new CEO Shreehas Tambe recasts Biocon as global medicines player
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth